Aerovate Therapeutics (AVTE) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

AVTE Stock Forecast


Aerovate Therapeutics stock forecast is as follows: an average price target of $13.00 (represents a 388.72% upside from AVTE’s last price of $2.66) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.

AVTE Price Target


The average price target for Aerovate Therapeutics (AVTE) is $13.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $2.00. This represents a potential 388.72% upside from AVTE's last price of $2.66.

AVTE Analyst Ratings


Hold

According to 5 Wall Street analysts, Aerovate Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for AVTE stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 5 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Aerovate Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 17, 2024Liisa BaykoEvercore ISI$2.00$1.6521.21%-24.81%
Jun 17, 2024Eun YangJefferies$2.00$1.6521.21%-24.81%
Apr 01, 2024Tiago FauthWells Fargo$35.00$29.5718.36%1215.79%
Mar 25, 2024Eun YangJefferies$65.00$26.95141.19%2343.61%
Row per page
Go to

The latest Aerovate Therapeutics stock forecast, released on Jun 17, 2024 by Liisa Bayko from Evercore ISI, set a price target of $2.00, which represents a 21.21% increase from the stock price at the time of the forecast ($1.65), and a -24.81% decrease from AVTE last price ($2.66).

Aerovate Therapeutics Price Target by Period


1M3M12M
# Anlaysts--4
Avg Price Target--$26.00
Last Closing Price$2.66$2.66$2.66
Upside/Downside-100.00%-100.00%877.44%

In the current month, the average price target of Aerovate Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aerovate Therapeutics's last price of $2.66. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jun 18, 2024Wells FargoOverweightEqual-WeightDowngrade
Jun 17, 2024Cowen & Co.-HoldDowngrade
Jun 17, 2024Guggenheim-NeutralDowngrade
Jun 17, 2024Jefferies-HoldDowngrade
Jun 17, 2024BTIGBuyNeutralDowngrade
Apr 01, 2024Wells FargoOverweightOverweightHold
Dec 06, 2022BTIG-BuyUpgrade
Row per page
Go to

Aerovate Therapeutics's last stock rating was published by Wells Fargo on Jun 18, 2024. The company Downgrade its AVTE rating from "Overweight" to "Equal-Weight".

Aerovate Therapeutics Financial Forecast


Aerovate Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast$6.82M$6.79M$6.75M--------
High Forecast$6.82M$6.79M$6.75M--------
Low Forecast$6.82M$6.79M$6.75M--------
# Analysts111--------
Surprise %-----------

Aerovate Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AVTE's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Aerovate Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts111--------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict AVTE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aerovate Therapeutics's previous annual EBITDA (undefined) of $NaN.

Aerovate Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts111--------
Net Income-----------
Avg Forecast$-17.74M$-16.54M$-15.76M$-21.08M$-3.46M$-5.20M$-7.07M$-8.51M$-11.62M$-16.16M$-23.65M
High Forecast$-17.74M$-16.54M$-15.76M$-21.08M$-3.46M$-5.20M$-7.07M$-5.11M$-5.52M$-16.16M$-23.65M
Low Forecast$-17.74M$-16.54M$-15.76M$-21.08M$-3.46M$-5.20M$-7.07M$-11.64M$-17.43M$-16.16M$-23.65M
Surprise %-----------

Aerovate Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AVTE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Aerovate Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts111--------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

Aerovate Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to AVTE last annual SG&A of $NaN (undefined).

Aerovate Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts111--------
EPS-----------
Avg Forecast$-0.61$-0.57$-0.55$-0.73$-0.12$-0.18$-0.24$-0.29$-0.40$-0.56$-0.82
High Forecast$-0.61$-0.57$-0.55$-0.73$-0.12$-0.18$-0.24$-0.18$-0.19$-0.56$-0.82
Low Forecast$-0.61$-0.57$-0.55$-0.73$-0.12$-0.18$-0.24$-0.40$-0.60$-0.56$-0.82
Surprise %-----------

According to undefined Wall Street analysts, Aerovate Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AVTE previous annual EPS of $NaN (undefined).

Aerovate Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ANTXAN2 Therapeutics$1.30$8.75573.08%Buy
AVTEAerovate Therapeutics$2.66$13.00388.72%Hold
OPTOpthea$3.28$14.00326.83%Buy
ANEBAnebulo Pharmaceuticals$1.52$6.00294.74%Buy
ACRVAcrivon Therapeutics$6.50$21.83235.85%Buy
RZLTRezolute$5.01$13.50169.46%Buy
ADAGAdagene$2.09$5.00139.23%Buy
MLYSMineralys Therapeutics$12.60$30.00138.10%Buy

AVTE Forecast FAQ


Is Aerovate Therapeutics a good buy?

No, according to 5 Wall Street analysts, Aerovate Therapeutics (AVTE) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of AVTE's total ratings.

What is AVTE's price target?

Aerovate Therapeutics (AVTE) average price target is $13 with a range of $2 to $35, implying a 388.72% from its last price of $2.66. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Aerovate Therapeutics stock go up soon?

According to Wall Street analysts' prediction for AVTE stock, the company can go up by 388.72% (from the last price of $2.66 to the average price target of $13), up by 1215.79% based on the highest stock price target, and down by -24.81% based on the lowest stock price target.

Can Aerovate Therapeutics stock reach $4?

AVTE's average twelve months analyst stock price target of $13 supports the claim that Aerovate Therapeutics can reach $4 in the near future.

What are Aerovate Therapeutics's analysts' financial forecasts?

Aerovate Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-24.245M (high $-20.839M, low $-27.367M), average SG&A $0 (high $0, low $0), and average EPS is $-0.84 (high $-0.722, low $-0.948). AVTE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $20.37M (high $20.37M, low $20.37M), average EBITDA is $0 (high $0, low $0), average net income is $-71.128M (high $-71.128M, low $-71.128M), average SG&A $0 (high $0, low $0), and average EPS is $-2.464 (high $-2.464, low $-2.464).